Hospitals & Managed Care

The question

Is the managed-care cohort permanently impaired by the 2024 utilization shock -- seniors returning to deferred procedures, Medicaid risk pools adversely selected by redetermination, and Medicare Advantage rate notices that compress margins -- or is this the mid-phase of a reference-class MLR reset that resolves over six-to-ten quarters with identifiable catalysts?

Base rates

The reference class is prior MLR reset cycles: 2008-2009, 2013-2014 following the initial ACA enrollment shock, and 2016-2017. In each episode, the large-cap managed-care composite compressed consensus earnings estimates by 10-20% over two quarters, the group traded at 11-13x forward earnings at the trough, and recovery to normalized margin took roughly six to eight quarters from the first negative guidance print. Total return from the trough quarter over the following three years averaged roughly 60-90% for the big-four insurers, versus roughly 35-45% for SPY over the same windows.

Hospital operator base rates are different. For-profit hospitals tend to benefit from the same utilization surge that pressures insurers -- higher volumes, higher acuity mix, and a stronger payer mix as commercial utilization normalizes alongside senior volumes. In the 2013-2014 reset, HCA-equivalent operators returned roughly 120% over the following three years. That dispersion inside the subsector is what makes this a book rather than a single-name trade.

Healthcare overall has trailed SPY meaningfully over the trailing twelve months, with managed-care drawdowns deeper than the sector average. The starting point is not pretty. It is also the starting point that has historically produced above-index three-year outcomes when the reference class catalysts fire on schedule.

Why consensus is wrong

Consensus currently assumes that elevated utilization is a new baseline rather than a reset phase. That assumption drives three mistakes.

First, the Medicare Advantage star-rating cycle is treated as a permanent penalty. Stars are computed annually and have measurable denominator effects. Plans that lost stars in the 2024-2025 cycle have identifiable measure-level paths back, and the rebid timing is public. The market is pricing a structural loss where the cycle has a known period.

Second, Medicaid redetermination has largely completed. The adversely-selected pool that remained post-redetermination is now the pool. Pricing adequacy for the 2026 and 2027 contract years is being repriced in open rate negotiations with state partners. The market is still pricing the transition risk after the transition has ended.

Third, the integrated care and pharmacy-benefit assets inside UNH, CI, and ELV are being valued at the same multiple as the insurance book, despite generating cash flow with different unit economics. Optum, Evernorth, and Carelon together represent a meaningful share of operating profit that is not a pure insurance franchise. Separating those is part of the analytical work the consensus is skipping.

This is not a "cover your eyes and buy UNH" trade. It is a reference-class rebuild where the identifiable catalysts -- star-rating cycle, rate notice sequencing, and Medicaid rate resets -- have a knowable shape.

Position construction

The book has four anchors and a set of supporting positions.

Integrated managed-care anchors (~64%). UNH at ~20.0% is the largest single position: the most diversified integrated-care asset base, the deepest Optum cash flow layer, and the widest set of measure-level star recovery paths. HCA at ~20.0% is the hospital-side anchor and the counterweight -- its volumes rise in the same environment that pressures insurers, and it has historically recovered faster than the group in reset cycles. CI at ~18.5% owns Evernorth and a commercial-heavy insurance book with less Medicare Advantage rate exposure than UNH or HUM. ELV at ~18.2% carries Carelon and a state-government-heavy footprint that benefits from Medicaid rate resets.

Focused managed-care exposure (~10%). HUM at ~7.7% is the cleanest Medicare Advantage pure-play in the book -- sized smaller than the integrated names because the star-rating recovery path is more concentrated. MOH at ~2.4% provides Medicaid-heavy exposure with a duration-risk profile that aligns with state-level rate negotiation cycles.

Hospital operators and post-acute (~10%). THC at ~4.1% adds for-profit hospital exposure with a growing ambulatory surgery center mix. UHS at ~3.0% provides acute-care and behavioral health exposure. ACHC at ~0.5% is the smallest position: behavioral health with ongoing operating and regulatory review items.

Specialty services (~5.5%). CNC at ~4.0% provides Medicaid managed-care depth alongside ELV and MOH. CHE at ~1.5% owns the VITAS hospice franchise and Roto-Rooter, a cash-generating composite that sits at a different multiple than the insurance book and provides ballast.

Asymmetric payoff

If the MLR reset follows the 2013-2014 shape -- six-to-eight quarters of normalization, star-rating recovery in the 2027 bid cycle, and hospital operator volumes continuing to run above the 2019 baseline -- weighted book returns track 18-24% annualized over three years. In the bear case where utilization stays elevated through 2027 and the 2026 MA rate notice is worse than 2024's, returns track -5% to +5%. In the bull case where MLR resets finish by late 2026 and star-rating recovery is ahead of schedule, returns push toward 30-35% annualized.

At 50% base, 30% bear, and 20% bull weightings, expected value clears the SPY base rate. The hospital operator anchor at 20% of the book is deliberate: it makes money when the insurance side hurts, and it compounds when the insurance side recovers.

Three things that would change our mind

1. A 2026 or 2027 Medicare Advantage rate notice that extends the rate compression cycle beyond the historical reset period, suggesting the current regime is a structural rather than cyclical adjustment.
2. Evidence from 2026 pricing cycles that Medicaid state partners are unable or unwilling to pass through actuarially adequate rates, which would permanently impair the government-programs earnings base.
3. Durable deterioration in the commercial insurance risk pool -- a persistent medical trend above pricing trend for four consecutive quarters -- that signals the reset is broader than senior utilization normalization.

What we're explicitly NOT betting on

We are not betting on a single star-rating reversal at any one plan. We are not betting on a specific legislative outcome around site-of-service parity or Medicare Advantage audit enforcement, though both tails matter. We are not betting on GLP-1 cost pass-through specifics. We are not betting on smaller pure-play insurers whose single-state exposure falls outside the reference-class base rates we priced. The thesis requires only that MLR reset cycles behave like MLR reset cycles have behaved for three prior episodes, and that hospital operators continue to absorb the elevated utilization side of the trade. Both are strictly weaker claims than picking winners, and the book is sized for them.